MedTrace Logo

A Study of the ILB-3101 in Patients with Advanced Solid Tumors

NCT06426680 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2024-12-09

No results posted yet for this study

Summary

ILB-3101 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of ILB-3101 in Chinese advanced solid tumor patients.

Conditions

  • Advanced Solid Tumor

Interventions

BIOLOGICAL

ILB-3101

There are eight escalating dose cohorts.

Sponsors & Collaborators

  • Innolake Biopharm

    lead INDUSTRY

Principal Investigators

  • Jian Zhang, MD · Fudan University

  • Hongxia Wang · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-30
Primary Completion
2025-12-31
Completion
2026-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06426680 on ClinicalTrials.gov